论文部分内容阅读
本研究探讨了载药纳米微球(NP)作为血管内靶向定位药物控释载体的可行性,通过最佳配方和导入条件的筛选为临床研究提供了基础.用聚乳酸-乙醇酸共聚物(PLGA)制备了包载抗细胞增生药物细胞松驰素B的生物降解性纳米微球.用狗为实验动物研究了正常血液循环条件下,纳米微球在血管内的吸收和定位的可能性和最佳条件.结果表明载药纳米微球可穿透结缔组织并被靶部位的血管壁吸收,可以用介入方法将NP导入血管内病灶部位,并使其在血管局部组织内缓慢释放药物,从而维持长期局部有效药物浓度,可达到有效地治疗心血管再狭窄及其他血管疾病的目的.
In this study, we investigated the feasibility of drug-loaded nanospheres (NPs) as a controlled release carrier for intravascular targeting drug delivery and provided the basis for clinical studies through screening of optimal formulation and introduction conditions.Using polylactic-co-glycolic acid (PLGA) was prepared biodegradable nanospheres containing anti-cell proliferative drug cytochalasin B. Using dogs as experimental animals to study the normal blood circulation conditions, the possibility of nano-microspheres in the blood vessels to absorb and locate And the best conditions.The results showed that drug-loaded nanospheres can penetrate the connective tissue and be absorbed by the vascular wall of the target site, the NP can be introduced into the intravascular lesion site by interventional method and slowly release the drug in the local tissue of the blood vessel, Thus maintaining long-term local effective drug concentration, which can achieve the purpose of effectively treating cardiovascular restenosis and other vascular diseases.